If you do not find an answer to your question here, contact us using the Contact Us form for a prompt response:
EPIFLO® is available through doctors, hospitals, clinics, skilled nursing facilities, and direct from Ogenix. Our clinical database shows that the average treated wound over 60 days old heals in 6-8 weeks, though some wounds heal faster and some take longer. You may be eligible for reimbursement from your insurance company already, and if not, we will work with you to get EPIFLO treatment approved in advance. For Medicare patients, after successful treatment, we encourage you to appeal to CMS for reimbursement. Call us at 781-702-6732 or use our contact page for more details or if you are ready to place your order.
EPIFLO is a Class III medical device and the FDA requires a prescription for its use. Oxygen is a safe and effective way to treat many types of wounds and is widely used in wound care. However it is important that EPIFLO be applied by a wound care professional. Though application is simple and takes seconds, proper application by a trained professional will ensure that maximized benefits are received by the patient.
EPIFLO® is a highly effective treatment for indications including Diabetic Foot Ulcers, Venous Leg Ulcers and Venous Stasis, Pressure Sores, Burns, Infections and others. EPIFLO® greatly reduces the cost of wound treatment to private payers by closing wounds and minimizing treatment time. Further, competing treatments such as Negative Pressure Wound Therapy and Hyperbaric Oxygen Therapy are very expensive when compared with EPIFLO®. Many case studies are available in which EPIFLO® has closed wounds which have previously failed other such treatments.
Many insurance companies will cover EPIFLO® on a case by case basis, and our reimbursement department can inquire on your behalf. Also, many skilled nursing facilities and long term care facilities use EPIFLO® for the cost savings alone. The economic benefits to EPIFLO® vs. other treatments are compelling, as EPIFLO® is priced at 25-50% less than currently accepted therapies and often works faster to close wounds. If you are a Medicare patient, Ogenix is working diligently towards securing reimbursment.
EPIFLO® received FDA 510K Clearance as a Class 3 medical device and has also been approved as a Class II medical device by Health Canada where no prescription is required for purchase.
Ogenix receieved CE Mark approval for sale in the EU and elsewhere in February, 2009. Contact us for more information.
The FDA has required that the kink and crush resistant cannulas that come with each EPIFLO be changed every time a dressing change is performed. They cannot be cut and reused. The FDA has also stipulated, however, that the cannula may be cut with a sterile scalpel when new in order to adjust the length. EPIFLO includes 4 cannulas with our 15 day devices which is sufficient for most wounds. Contact Ogenix if additional cannulas are needed.